Charles River to Perform Plasmid Production for Ship of Theseus
2024年4月4日 - 9:00PM
ビジネスワイヤ(英語)
GMP grade plasmid DNA to serve as a direct
therapeutic targeting various indications
Charles River Laboratories International, Inc. (NYSE: CRL) and
Ship of Theseus, a therapeutics company developing
degradation-resistant homeobox (HOX) family biologics, today
announced a Good Manufacturing Practice- (GMP) plasmid DNA contract
development and manufacturing organization (CDMO) agreement. Ship
of Theseus will leverage Charles River’s premier expertise to
manufacture GMP plasmid DNA to serve as the active drug substance
for its lead candidate.
Ship of Theseus is developing a proprietary suite of biologics
based on the HOX family of transcription factors, which are
responsible for driving the differentiation of tissue stem cells
towards their respective lineages to repair and maintain the
correct function of tissues and organs. Proprietary modifications
may enable these regulators to be used as therapeutics.
The collaboration between Charles River and Ship of Theseus will
support therapeutic development for a broad variety of target
indications such as diabetic and chronic wounds, neutropenia,
psoriasis, androgenetic alopecia, women’s health and infertility,
and epithelial cancers. Charles River’s GMP plasmid DNA CDMO center
of excellence based in Keele, United Kingdom will lead the
collaboration, providing services that include plasmid DNA backbone
generation, plasmid synthesis, GMP master cell bank (MCB)
generation, pre-production evaluation, and GMP plasmid DNA
manufacture including in-house release testing.
Plasmid DNA Manufacturing Services
In recent years, Charles River has significantly broadened its
cell and gene therapy portfolio with several acquisition
integrations and expansions to simplify complex supply chains and
meet growing demand for plasmid DNA, viral vector, and cell therapy
services. Combined with the Company’s legacy testing capabilities,
Charles River offers an industry-leading “concept to cure” advanced
therapies solution.
With plasmid product and service offerings spanning
off-the-shelf and custom production of research, High Quality (HQ)
and GMP grade DNA, the Company leverages its eXpDNA™ plasmid
manufacturing platform built on established processes and
fine-tuned over decades successfully supporting vaccine and
advanced therapy clients through clinical trials and beyond.
Available on-demand is a 30-minute case study webinar led by Dr.
Andrew Frazer, Associate Director, Scientific Solutions, Gene
Therapy CDMO Services, that explores the role of plasmid DNA as a
critical starting material, the latest advancements in associated
regulatory guidance to safeguard your therapeutic programs, and
case studies demonstrating expedited development and manufacture of
ATMPs: https://bit.ly/3Vl5rgu
Approved Quotes
- “We are thrilled to work with Ship of Theseus to produce GMP
plasmid DNA to help advance the organization’s mission to develop
HOX family biologics. Charles River’s robust plasmid DNA
manufacturing portfolio and track record makes us the ideal
candidate to produce this critical material which has the potential
to impact numerous patient indications.” – Kerstin Dolph, Corporate
Senior Vice President, Global Manufacturing, Charles River
- “Ship of Theseus is proud to collaborate with Charles River as
our manufacturing partner of choice. We trust the team’s decades of
success developing, producing, and reliably delivering plasmid DNA
and look forward to bringing our therapies to patients.” – Jeremy
Elser, Founding CEO, Ship of Theseus
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
About Ship of Theseus
Ship of Theseus develops therapeutics across diverse indications
by leveraging the homeobox (HOX) family of transcription factors.
Utilizing the broad and powerful cell regulatory capabilities of
the HOX family, Ship of Theseus and its indication-specific
subsidiaries are targeting an array of indications, with early
emphasis on topicals for chronic wounds. Proprietary modifications
improve intracellular dynamics and half-life, overcoming
prohibitive shortcomings in the endogenous sequences.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240404958978/en/
Charles River Investor: Todd Spencer Corporate Vice
President, Investor Relations 781.222.6455 todd.spencer@crl.com
Charles River Media: Amy Cianciaruso Corporate Vice
President, Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Ship of Theseus Investor: Jeremy Elser, PhD Chief
Executive Officer jeremy@ship-of-theseus.com
Charles River Laboratories (NYSE:CRL)
過去 株価チャート
から 5 2024 まで 6 2024
Charles River Laboratories (NYSE:CRL)
過去 株価チャート
から 6 2023 まで 6 2024